[1]. D. Planchard SP, K. Kerr, S. Novello, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29: iv192–iv237.
[2]. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015;26: 1883-1889.
[3]. Zhou CC, WY, Chen GY, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12: 735-742.
[4]. Mitsudomi T MS, Yatabe Y, Negoro S, et al, for the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11.
[5]. Susumu Kobayashi S BT, Dayaram T, Jänne PA, et al. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. N Engl J Med 2005;352: 786-792.
[6]. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17: 1616-1622.
[7]. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19: 2240-2247.
[8]. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4: 1046-1061.
[9]. Wu YL AM, Garassino MC, Han JY, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol 2018;36: 2702-2709.
[10]. Goss G, Tsai C-M, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016;17: 1643-1652.
[11]. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol 2017;35: 1288-1296.
[12]. Mok TS WY, Ahn MJ, Garassino MC, et al, for the AURA3 Investigators. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med. 2016;376(7): 629-640.
[13]. Soria JC OY, Vansteenkiste J, Reungwetwattana T, et al; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med 2018;378: 113-125.
[14]. Ramalingam SS, Vansteenkiste J, Planchard D, et al, Investigators F. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382: 41-50.
[15]. Hu F, Xu J, Zhang B, et al. Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. Clinical Lung Cancer 2018;20(1): e81-e90.
[16]. Xu QH, Zhou F, Liu H, et al. Considative Local AblativeTherapy Improves the Survival of Patients With SynchronousOligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR -TKIs. J Thorac Oncol 2018;13: 1383-1392.
[17]. Weickhardt AJ, Scheier B, Burke JM, et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer. J Thorac Oncol. 2012;7: 1807–1814.
[18]. Gomez DR, Blumenschein Jr GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after fi rst-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17: 1672-1682.
[19]. Gomez DR, Tang C, Zhang JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional,Phase II, Randomized Study. J Clin Oncol 2019;37: 1558-1565.
[20]. Hayakawa D, Takahashi F, Mitsuishi Y, et al. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Thorac Cancer 2020;11: 140-149.
[21]. Mu Y, Hao X, Xing P, et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J Cancer Res Clin Oncol 2020.
[22]. Guo TT, Ni JJ, Yang X, et al. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2020;107: 62-71.
[23]. Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol 2019;14: 2109-2119.
[24]. Al-Halabi H SK, Digamurthy SR, Niemierko A, et al. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol 2015;10: 1601–1607.
[25]. Schmid D, Klingbiel D, Aepplia S, et al. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019;130: 149–155.
[26]. Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013;79: 33-39.
[27]. Chan OSH, Chi Lam K, Li JYC, et al. ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases of NSCLC After EGFR TKI. Lung Cancer 2020;142: 41-46.
[28]. Wang S, Yan B, Zhang Y, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Int J Cancer 2019;144: 2880-2886.
[29]. Parikh RB, Cronin AM, Kozono DE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;15: 880-887.
[30]. Luketich JD, Martini N, Ginsberg RJ et al. Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thoracic Surg 1995;60(6): 1609–1611.
[31]. Johnson KK, Rosen JE, Salazar MC, et al. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer. Ann Thorac Surg 2016;102(4): 1166-1171.
[32]. Miyawaki E, Kenmotsu H, Mori K, et al. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiation Oncol Biol Phys 2019.
[33]. Iyengar P Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for LimitedMetastatic Non–Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4: e173501.
[34]. Lee JH, Chen H, Hsu FM, et al. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. The Oncologist 2019;24: e1417–e1425.